Roche Won't Extend Offer for Illumina as Shareholders Re-elect Flatley, Others to Board | GenomeWeb

This article has been updated with comments from an internal Illumina e-mail.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche will not extend its tender offer for Illumina, the Swiss pharmaceuticals and diagnostics firm said today, ending its hostile bid for the San Diego firm for now.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.